HOME >> BIOLOGY >> NEWS
Welch Award honors McConnell for insights into physical chemistry, cell membranes

ear magnetic resonance (NMR) data to the structure of molecules. He modified the equations governing NMR to include the effects of chemical reactions, and used the results to measure chemical kinetics, i.e., the speed at which reactions take place. He has also pioneered research on free radicals an extremely reactive type of chemical that occurs in chemical and biological settings; this ultimately led to the development of the McConnell Relation, which describes the distribution of electron spin in free radicals.

When Dr. McConnell moved to Stanford University in 1964, he began to use the methods of physical chemistry to study biological problems. There, he introduced a method called spin labels, in which electron and NMR spectra are used to study the structure and kinetics of proteins and lipids. His work showed how to measure the movement of molecules through and within membranes in the laboratory; this was later shown by many researchers to apply to living cell membranes. His research also showed how a protein present in the body combines with that of a foreign peptide on the cell membrane to enable the body to recognize a pathogenic invader.

Some of these discoveries are critical to understanding many properties of membranes, says Dr. McConnell, and a large portion of biology takes place in and on membranes, so understanding them is crucial.

Dr. McConnells recent work has focused on the behavior of cholesterol in membranes. Discoveries by his team concerning the properties of monomolecular films on the surface of water have shed light on cholesterol-phospholipid interactions that previously had puzzled scientists in several different fields of research.

Cholesterol forms special condensed complexes, says Dr. McConnell. By describing them mathematically, one can predict many of the properties that have been observed regarding cholesterol and phospholipid mixtures, which are major components of animal cell membranes. He believes th
'"/>

Contact: Melissa Quiroz
mquiroz@hillandknowlton.com
713-752-1916
The Welch Foundation
30-May-2002


Page: 1 2 3

Related biology news :

1. Harden McConnell named winner of 2002 Welch Award in Chemistry
2. Welch honors Kornberg for insights into DNA transcription
3. Welch Award honors 2 for unlocking natures secrets
4. Gladstone investigator Mike McCune wins prestigious NIH Directors Pioneer Award
5. UT Southwestern biochemist honored with NIH Directors Pioneer Award
6. Award winning researchers reveal potential new role for Glivec
7. UMaine anthropologist wins Solon T. Kimball Award
8. Secretary of Energy announces seven E.O. Lawrence Award Winners
9. Martin Saunders to receive the James Flack Norris Award
10. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
11. NJIT professor receives Presidential Award for breakthrough research with adult stem cells

Post Your Comments:
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: